Unraveling the Complex Immune Response: A New Perspective on CAR T Cell Therapy Side Effects
A groundbreaking study reveals a common immune root cause for severe side effects following CAR T cell therapy for multiple myeloma. This therapy, designed to target cancer cells, has shown remarkable success, but its side effects can be life-threatening. The research, presented at the 67th American Society of Hematology (ASH) Annual Meeting, sheds light on a new type of immune-related adverse event, offering insights that could revolutionize patient care.
The study, conducted by scientists from the Abramson Cancer Center and Penn's Perelman School of Medicine, identified a specific immunological profile linked to neurotoxicity, intestinal inflammation, and high mortality rates. These side effects, known as CAR T-associated immune-related adverse events (CirAE), can occur weeks or months after treatment, posing a significant challenge for healthcare professionals.
Unveiling the Immune Mechanism
The research team analyzed data from 198 patients who received two FDA-approved BCMA-CAR T cell therapies. They discovered that CirAE was significantly more prevalent with one therapy (cilta-cel) compared to the other (ide-cel). Moreover, patients with CirAE had a higher risk of non-relapse mortality, primarily due to infections, which were linked to higher cumulative steroid exposure.
The study's key finding was the identification of CD4+ CAR T cells as the primary mediators of CirAE. These cells exhibited a unique gene signature and elevated expression of effector molecules, contributing to tumor killing. The team also noted a higher proportion of circulating CD4+ T-cells post-infusion in patients with CirAE, further emphasizing the role of these cells in the adverse events.
A Case Study Inspires Further Exploration
A notable case study inspired the research: a patient with the highest CAR T expansion ever recorded at Penn, who experienced multiple CirAEs. This case motivated the team to delve deeper, leading to the discovery of a specific circuit (IL-15–CCL5–CCR5) driving the proliferation of CD4+ CAR T cells. Preclinical tests demonstrated that blocking CCR5 could safely control CAR T cell expansion while maintaining their cancer-fighting capabilities.
Addressing the Challenge
The research team has already implemented changes in patient treatment protocols at Penn Medicine. High-risk patients, identified by specific biomarkers, are now given a brief course of steroids to manage excessive CD4+ CAR T expansion. This approach aims to prevent CirAE and reduce mortality rates.
Looking Ahead: A Steroids-Free Strategy
The ultimate goal is to develop a steroids-free strategy, which would be less toxic for patients. The team's findings suggest that targeting CCR5 could be a promising approach to protect against CirAE without compromising the therapy's effectiveness.
The research team invites further exploration of this targeted strategy and encourages ongoing research to address CirAE. The study's findings will be presented at ASH, offering a platform for the scientific community to engage in discussions and advance our understanding of CAR T cell therapy's complexities.
